NUIX LIMITED (NXL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NXL

NXL - NUIX LIMITED

FNArena Sector : Software & Services
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: 0.51
Index: ALL-ORDS | ALL-TECH

Nuix is an Australian technology company providing investigative analytics and intelligence software for transforming large amounts of data into actionable intelligence. The company listed in December 2020.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.785

30 Oct
2026

-0.090

OPEN

$1.87

-4.80%

HIGH

$1.89

689,672

LOW

$1.78

TARGET
$3.00 68.1% upside
OTHER COMPANIES IN THE SAME SECTOR
360 . ALC . AMX . AR9 . ATA . AV1 . BMT . COS . DOC . EIQ . GTK . KYP . PPL . RDY . SKO . UBN . VGL . XF1 . YOJ .
FNARENA'S MARKET CONSENSUS FORECASTS
NXL: 1
Title FY25
Actual
FY26
Actual
FY27
Forecast
FY28
Forecast
EPS (cps) xxx 4.9 8.6 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A 75.2% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 20.6 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

$ 

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx4.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx263.2 M
Book Value Per Share xxxxxxxxxxxxxxx92.4
Net Operating Cash Flow xxxxxxxxxxxxxxx60.7 M
Net Profit Margin xxxxxxxxxxxxxxx6.25 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx5.45 %
Return on Invested Capital xxxxxxxxxxxxxxx5.10 %
Return on Assets xxxxxxxxxxxxxxx3.34 %
Return on Equity xxxxxxxxxxxxxxx5.45 %
Return on Total Capital xxxxxxxxxxxxxxx9.59 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx58.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx38 M
Total Debt xxxxxxxxxxxxxxx41 M
Goodwill - Gross xxxxxxxxxxxxxxx42 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx70 M
Price To Book Value xxxxxxxxxxxxxxx1.31

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx23.4 M
Capex % of Sales xxxxxxxxxxxxxxx8.89 %
Cost of Goods Sold xxxxxxxxxxxxxxx76 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx156 M
Research & Development xxxxxxxxxxxxxxx36 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

26/08/2026

1

Overweight

$3.00

68.07%

Nuix's FY26 result was well ahead of Morgan Stanley's expectations, with underlying EBITDA beating the broker's forecast by 18%, while ACV reached $260m, up 14% y/y versus 12% expected.

The standout was Nuix Neo, with ACV surging 179% to $79m and the platform now accounting for 30% of group ACV. The analyst believes Nuix is emerging as an AI winner.

Neo's strong customer uptake is accelerating new customer wins and increased spending from existing customers, supporting stronger revenue and earnings growth.

FY27 guidance is for ACV growth of 10%-15% to $285m-$300m, despite Nuix stepping up product R&D investment by around 25%. FY27-FY29 EBITDA forecasts rise by 6%-10% and EPS forecasts by 9%-27%, respectively.

Overweight retained along with a higher target of $3 from $2.50 target. Industry View: Attractive.

FORECAST
Morgan Stanley forecasts a full year FY27 dividend of 0.00 cents and EPS of 8.60 cents.
Morgan Stanley forecasts a full year FY28 dividend of 0.00 cents and EPS of 9.70 cents.

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

22/10/2026

1

Buy

$3.33

86.55%

Moelis maintains a Buy rating for Nuix with a $3.33 target price as expanding adoption of artificial intelligence creates strong demand tailwinds for unstructured data governance and security.

Nuix trades at 1.8x FY27 EV/Revenue, representing the lower end of its three-year range following a significant transformation in earnings and cash flow performance since 2023.

Moelis notes an additional one-off -$15m R&D investment planned in FY27 to support AI-enabling features within Nuix Neo, including MCP Server and Neo Agent capabilities.

Management identifies an ideal customer target cohort of 10,000 organisations holding over 50TB of unstructured data, representing a $5bn-plus market opportunity with current penetration under 10%.

Moelis views current valuation multiples as implying limited market recognition of growth opportunities across agentic workflow and compliance automation solutions.

FORECAST
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of 9.70 cents.
Moelis forecasts a full year FY28 dividend of 0.00 cents and EPS of 9.80 cents.

NXL STOCK CHART